Shingles Vaccine Can Reduce Risk of Stroke And Heart Attack, Study Finds
A new study highlights a perhaps unexpected way to reduce your risk of cardiovascular disease: getting vaccinated against shingles.
Cardiovascular disease – involving the heart or blood vessels – is by far humanity's leading cause of death. It kills about 18 million people globally each year, mostly via heart attack or stroke.
While this is a daunting public health problem, medical science has revealed ways to lower risk: A heart-healthy diet helps, as do exercising daily, getting enough sleep, managing stress, and avoiding smoking.
According to the new study, covering data on more than 1.2 million people in South Korea over the age of 50, those who received a shingles vaccine showed a 23 percent lower risk of cardiovascular events overall.
This protection lasted for up to eight years, with the greatest reduction in risk observed two to three years after vaccination.
The effect was more pronounced in men, people younger than 60, and those with unhealthy behaviors such as smoking, drinking alcohol, or inactivity.
A shingles vaccination is already widely recommended for adults over 50 to protect against the viral disease, known for its painful skin rash and blisters.
Shingles is caused by the varicella-zoster virus – the culprit behind chickenpox. After people recover from chickenpox, typically in childhood, the virus can remain dormant in nerve cells for years or decades, then abruptly reactivate.
The immediate effects of shingles are bad enough, but while the rash usually fades in a few weeks, the disease can be insidiously persistent, explains pediatrician researcher Dong Keon Yon from Kyung Hee University in South Korea.
"Shingles causes a painful rash and can lead to serious complications, especially in older adults and those with weak immune systems," Yon says. "Research shows that, without vaccination, about 30 percent of people may develop shingles in their lifetime."
The most common complication is long-term nerve pain that can last for months or years. Shingles near the eyes can also lead to vision loss, and some people develop lasting neurological problems.
Recent research suggests shingles also raises stroke and heart attack risk. "In addition to the rash, shingles has been linked to a higher risk of heart problems, so we wanted to find out if getting vaccinated could lower this risk," Yon says.
The researchers merged data from several South Korean government agencies, ultimately studying more than 1.2 million people. Spanning 2012 to 2021, this included information on vaccination status as well as cardiovascular health and other relevant factors.
Vaccinated people had a 23 percent lower risk of cardiovascular events overall, including a 22 percent lower risk of coronary heart disease, a 26 percent lower risk of heart failure, and a 26 percent lower risk of a major cardiovascular event like stroke or heart attack.
"The shingles vaccine may help lower the risk of heart disease, even in people without known risk factors," Yon says.
That would be big news if confirmed, but makes sense given what we know about shingles' short-term effects on the cardiovascular system.
"A shingles infection can cause blood vessel damage, inflammation, and clot formation that can lead to heart disease," Yon explains. "By preventing shingles, vaccination may lower these risks."
One of the largest and most comprehensive of its kind, the study has some limitations, the authors acknowledge. The sample lacks diversity, since all subjects are from South Korea.
"While we conducted rigorous analysis, this study does not establish a direct causal relationship, so potential bias from other underlying factors should be considered," Yon says.
The study only addresses the live zoster vaccine, which uses a weakened form of the virus. There's also a recombinant subunit vaccine for shingles, featuring just a viral protein, that's increasingly prevalent in many countries.
In addition, previous research suggests both shingles vaccines may also protect against dementia.
The study was published in the European Heart Journal.
Spikes of Bird Flu in Cats Could Be a Warning of a Future Pandemic
HIV Drugs Dramatically Lower Risk of Alzheimer's Disease, Study Finds
Measles Could Become Endemic in US if Surge Continues, Expert Warns
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10-06-2025
- Yahoo
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
10-06-2025
- Business Upturn
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) — AriBio Co., Ltd. ('AriBio'), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. Advertisement AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. 'This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide,' said Jai Jun Choung, CEO of AriBio. 'Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions.' 'We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries,' said Isabel Afonso, CEO of Arcera. 'This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs.' The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Yahoo
05-06-2025
- Yahoo
Why Can China Make Rapid Progress in Artificial Intelligence?
BEIJING, June 5, 2025 /PRNewswire/ -- Finding Answers in China from In 2025, China runs in a fast lane of artificial intelligence (AI) development as the country has made a series of breakthroughs in this frontier technology. For example, DeepSeek astonished the world with its high performance and lower cost, Unitree robots showed a stunning yangko dance at the Spring Festival Gala, and Beijing held the world's first humanoid robot half-marathon in this spring. In this episode, CICG's South Korean host Kim Eunji, along with KIM Jongmoon, Chief Representative of Korea Innovation Center (KIC China), explores Beijing's Yizhuang Economic-Technological Development Area which is home to many artificial intelligence startups. They try to find out the key to their success. Why Can China Make Rapid Progress in Artificial Intelligence? View original content to download multimedia: SOURCE Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
